Objective: We undertook this study to assess the agreement between fetal umbilical cord drug levels and maternal self-report.
Introduction
Maternal illicit drug use continues to be a significant problem, contributing to many obstetrical and neonatal/pediatric complications. 1 Many of these complications can be ameliorated by good obstetric care [2] [3] [4] and developmental interventions 5, 6 ; however, it is often difficult to obtain an accurate assessment of maternal drug usage, given the legal and social difficulties women face upon disclosing their drug use. Previous biological means to detect maternal drug use have relied on maternal urine, blood, and hair and fetal urine, meconium, and hair. These methods are all limited in their ability to reliably detect drug usage, especially given collection issues and a relatively narrow window of positivity. Conflicting reports exist on the sensitivity and specificity of biologic testing, specifically meconium, vis-a-vis maternal self-report. 7 Clearly, better methods are needed to reliably detect maternal drug usage.
Montgomery et al. 8 described using a segment of umbilical cord and correlated the values obtained by this means with those obtained with meconium, finding good correlation using mass spectrometry. In addition, they found that enzyme-linked immunosorbent assay (ELISA)-based tests 9 can be used to assess fetal exposure to drugs of abuse, with extremely high negative predictive values (>98%) compared with mass spectrometer.
Many complications of maternal drug usage may be also due to concomitant use of tobacco by the mother. No studies to date have reported this method of umbilical cord testing to confirm and quantify maternal tobacco use.
The aim of this paper was to correlate self-reported drug use during pregnancy with umbilical cord ELISA of five drugs of abuse in addition to quantifying cotinine levels, a stable metabolite of nicotine.
Methods

Sample collection
Cord samples were collected as a subproject of the larger Pacific Research Center for Early Human Development study (PRCEHD). PRCEHD is a cohort study, which banks de-identified placental and blood samples from women at delivery, and links these samples with a database of prenatal, delivery, and infant outcome information derived from medical record data. Approval was obtained from the University of Hawaii Institutional Review Board for the subproject as well as Western IRB for the larger PRCEHD study. Informed consent was obtained from the women for participation in the larger PRCEHD study. The subproject was deemed exempt as the clinical information and tissues were de-identified.
In all, 10 cm portions of each cord was collected from each placenta within 8 h of delivery, rinsed with phosphate-buffered saline, and frozen at À801C until processing.
Subjects
Women were identified as drug users if they either self-reported drug use during the course of their prenatal care or had a positive toxicology screen at any time during pregnancy. Screening for substance abuse was done by the treating physician, the admitting resident, and the admitting nurse, and was noted in the prenatal record, which was then downloaded into the database. Women were classified as smokers, if they admitted to smoking within a week of delivery. Controls were chosen randomly from the women in the database, with no noted pregnancy complications or substance use.
Processing of umbilical cord tissue samples
Before use, tissue pieces were thawed, wet weight was recorded, and tissues were homogenized 1:4 (w:v) in Tris-HCl buffer containing 5 mM MgCl 2 and 2 mM phenylmethylsulfonyl fluoride (pH 7.4). Homogenization was performed using a mechanical T10-Basic Laboratory Homogenizer at 6500 r.p.m. for B30 s per sample (IKA Labortechnik, Wilmington, NC, USA). After processing, whole umbilical lysates were aliquoted (8 to 10 aliquots per sample) then stored frozen at À80 1C until analysis. Immediately before assay, umbilical cord lysates were thawed and measured for protein content using the Bicinchoninic acid method with bovine serum albumin (free fatty acid fraction V; Sigma Chemical, St Louis, MO, USA) as a standard. 10 Detection and quantification of cotinine, amphetamine, and methamphetamine in umbilical cords All umbilical cord samples were assayed by blinded bench scientists using only four-digit numbers as identifiers. Each patient sample was quantified in triplicate using commercial ELISA kits for cotinine and methamphetamine as per the manufacturer's instructions (Immunalaysis, Pomona, CA, USA). Spectral detection was performed at l ¼ 450 and 650 ± 2 nm (SpectraMax Plus, Molecular Devices, Sunnyvale, CA, USA).
Cotinine levels in umbilical cords were quantified by comparison to a standard curve of cotinine (0, 5, 10, 25, 50, 100, and 500 ng ml -1 ) supplied by the manufacturer (Immunalaysis). Standard curves were constructed by fitting sigmoidal dose-response models (four-parameter logistic functions) to pure cotinine standards and interpolating the absorbance units (AU) of unknown samples. Results were subsequently normalized to mg of umbilical cord protein (results expressed as ng cotinine per ml per mg protein) allowing comparison between tissue samples.
Methamphetamine results were quantified using a standard curve of pure d-methamphetamine (Sigma Chemical) constructed in-house by serial dilution. Standard curves were performed with the following seven concentrations, each in triplicate: 1, 5, 10, 25, 50, 75, and 100 ng ml -1 and within the manufacturer's recommended linear range for the methamphetamine ELISA kit (1 to 50 ng ml -1 ). Again, the sigmoidal dose-response model was fitted to AU from the methamphetamine standards, and then concentrations of unknown samples were interpolated. Following quantification, the kit results (ng ml -1 ) were normalized to mg of umbilical cord protein (ng per ml per mg protein) to facilitate comparison between tissue samples.
Both assay blanks (buffer used to dilute samples, '0 ng ml -1 ') and true-negative samples (synthetic urine negative for the drug, supplied by the manufacturer) were included in each assay and these negative controls were used alongside the standard curves to assign the results. To be considered 'positive' (P), an unknown sample had to satisfy the following two conditions: each must have AU greater than that of both the assay and the true blanks combined:
Secondly, unknown samples had to return a quantifiable number derived by interpolation from the standard curve and were above the limit of detection for the curve (1 ng ml -1 ). Samples that met both criteria were termed 'positive' and those results are reported in ng per ml per mg protein. Samples with AU higher than Equation (1) criteria, but which could be quantified (that is where sample AU was above the limit of sensitivity of the standard curve at 1 ng ml -1 ), the absorbance reading was not >3 s.d. below assay blanks termed 'negative' but were re-assessed on a separate day by a different scientist. Those with AU below the blanks and outside the standard curve were termed 'negative' (N). Additional re-runs were performed for any sample, where the coefficient of variation (CV; Equation (2)) for the triplicate was X15%.
Coefficient of variation ðCVÞ ¼
Qualitative detection of amphetamine, cannabis, cocaine, and opiates in umbilical cords As standard curves were not available for these latter four assays, samples were designated 'positive,' 'potential positive,' or 'negative' as follows: triplicate wells for both an assay blank (buffer used to dilute samples) and a true negative (synthetic urine negative for drug, provided by the manufacturer) were included in each assay. Kit results were considered valid when both the assay blank and the negative control returned absorbance readings with a CVp15%. To be considered 'positive,' an unknown sample had to return an absorbance reading of >3 s.d. above the average absorbance of assay and true blanks combined (n ¼ 6 wells, Equation (1) above).
As the s.d. for triplicates averaged <5% for all ELISAs, a high degree of precision and accuracy for the assays was inferred. This allowed us to use a very stringent measure for assigning positive results, namely, average AU þ 3 s.d., which vastly reduces false positive (type I statistical error). However, as average þ 3 s.d. is such a stringent measure, any 'negative' patient samples with absorbance >2 s.d. from the negative control averages were called 'likely negative' but were repeated on a separate day by a different scientist. This was in an attempt to mitigate type II error (false negative) caused by either samples being close to the limit/s of detection of the commercial kits. While we wished to take a conservative position on assigning 'positive' samples without a standard curve (the use of þ 3 s.d. and insistence on at least two independent confirmations of positive status), we did not wish to artificially exclude any borderline positive samples, so these borderline samples were also re-assayed for stringency. If a second assay confirmed the initial trial, 'positive,' or 'negative' was assigned. Where second results contradicted the first, this sample was designated 'potential positive.' Statistical analysis and model fitting All quantitative analysis for ELISAs was performed using Prism 5.0 (GraphPad Prism, San Diego, CA, USA). Standard curves were fitted to a four-parameter logistic function (Hill curve, Sigmoidal doseresponse with variable slope) and fits were iterated to a maximum of 1000, until the equation best fit the data by moderately strict criteria (successive fits deviate by <0.001%). Goodness of fit was assessed by evaluation of Sy.x., R 2 values, and 95% confidence intervals. Standard curves were accepted if the fit converged and when both the negative control (supplied by the manufacturer) and the assay control (blank buffer tissue lysates were made in) returned 'zero' readings when they were interpolated from the standard curve. For triplicate determinations of any single sample, the CV cutoff was 15% for intraassay precision for the maximum allowable error. Samples with X15% CV were automatically re-tested.
Correlation with maternal drug use and smoking To arrive at the correlation between self-reported behaviors and umbilical cord values, Cohen's k values and 95% confidence intervals were calculated. 11 In addition, sensitivity, specificity, and positive and negative predictive values were calculated, comparing maternal self-report with drug cotinine and drug levels. Only those women who admitted use during pregnancy were included in these calculations. Only the confirmed positives were used in these calculations, potential positives were considered negative. Univariate analysis of the characteristics of the cohort was done with t-tests using SAS 9.1 (SAS, Cary, NC, USA).
Results
Characteristics of the full cohort studied have been previously reported. 12 Cords from 103 women were processed. Of these women, 28 admitted to using street drugs during pregnancy, of these 28, 71% were smokers, which decreased to 50% by the time of delivery. Thirty-five women were classified as persistent smokers, meaning smoking within 1 week of delivery, without other drug use. There were 38 healthy controls, women who denied any smoking, alcohol, or drug use on routine screening. See Table 1 for characteristics and full results of the cohort. Women in both the smoking and the drug groups did not differ in age, but did have significantly higher gravidity and parity.
Correlation of cotinine levels and self-reported smoking Of the self-reported persistent smokers, 13 (27%) had positive cotinine levels. Only one non-smoker had a positive cotinine level (12.5 mg/ml À1 mg À1 tissue). The calculated agreement between self-reported smoking and cord cotinine levels was fair (k ¼ 0.26; 95% confidence interval ¼ 0.7 to 0.5). Using self-reported smoking as the 'gold standard,' the sensitivity is 27%, specificity is 98%, positive predictive value is 93%, and negative predictive value is 60%. These results are shown in Table 2 . Detecting maternal drug use using umbilical cord TE Wright et al
Street drugs
Of the 28 women who admitted to using street drugs, 9 admitted to methamphetamine use in the third trimester, 12 admitted to methamphetamine use during pregnancy, but quit before the third trimester, and 3 of those women also admitted to marijuana use. Three women had a history of methamphetamine use, but quit before the current pregnancy. Three women admitted to polysubstance use, including marijuana, methamphetamines, and cocaine, and one woman admitted to just cocaine use. Interestingly, no women were noted to have used solely marijuana.
Cord analysis
Six cords (5.8%) were positive for either methamphetamine or amphetamine, three cords were possibly positive (one of two tests positive). Eighteen cords (17.5%) were positive for marijuana, with an additional six possibly positive. More cords were positive for meth in the control group than in the drug group, but this difference was not statistically different. Each of the three cords was positive or possibly positive for cocaine. Tables 3-5 
Discussion
These results show that umbilical cord tissue has a slight-to-fair correlation with self-reported substance use. We showed that umbilical cord ELISA has different sensitivities for different substances: for example, this test is more sensitive at picking up marijuana than methamphetamine and cotinine. This can be explained by the sensitivity of the kits themselves, which is controlled by the manufacturer and thus not under our control; affinity of drugs to various tissues; the pharmacology of drug distribution; and the characteristics of the k statistic, which is dependent on the prevalence of the exposures in question. 13 Umbilical cord tissue consists of a polymatrix of Wharton's jelly, which is made up of mucopolysaccharides. It contains one vein to carry oxygenated blood and nutrients to the fetus and two arteries carrying deoxygenated blood and fetal wastes back to the placenta. These vessels are lined with endothelia.
14 Based on these characteristics, and the very fat-soluble nature of drugs of abuse, the umbilical cord would not be expected to function as a good reservoir of drugs in the way that adipose or brain tissue might. In general, the half-lives of drugs of abuse are very short from as little Detecting maternal drug use using umbilical cord TE Wright et al as 1 to 2 h for cocaine up to B24 h for marijuana. This means that even in the case of marijuana, which has the longest systemic residence time, the terminal half-life (that is complete clearance of drug from the umbilical cord) would occur within 96 to 120 h (4 to 5 days). Meaning that unless the pregnant woman ingested the drug of abuse within a few days of birth, quantifying the drug would be difficult and variable. Montgomery et al.
8
showed a good agreement with umbilical cord tissue and meconium, but meconium, comprising mostly of intestinal epithelia, lanugo, mucus, amniotic fluid, bile, and water, is also very hydrophilic and thus should also be considered a poor matrix for methamphetamines and other drugs of abuse for the same reasons as described above. In our analysis, cotinine levels showed a better correlation with self-reported smoking than other drug use, which is similar to a report by Derauf et al., 15 who showed a good correlation (k ¼ 0.56) with cigarette smoking and meconium cotinine levels. However, as we have discussed, the umbilical cord and meconium are relatively hydrophilic so they could be expected to have the same or similar distribution and mean residence times for cotinine, making Derauf et al.'s conclusions empirically sensible. The real question, however, may not be related to fetal load of drugs at birth, but to quantify the amount of maternal drug use experienced by the fetus. While we did not have any other tissue or serum to run comparisons for these cords, which is a limitation of this paper, several important points in this respect are already known. For example, antipyrine (an amphetamine derivative) is used in placental perfusion experiments as a marker of pure diffusive transport, with effectively no barrier. 16 Most of the drugs of abuse studied herein (namely amphetamine, methamphetamine, THC, and opioids) have similar pharmacokinetic characteristics to antipyrine and would be expected to equilibrate across the placenta and umbilical cord into the fetal system. In contrast, cocaine and cotinine show differing, slightly less fat-soluble profiles. For example, cocaine is transferred across the placenta at only 80% the rate of antipyrine 17 and some studies have suggested that the placenta acts as a depot for cocaine accumulation preventing transfer to the fetus. 18 Additionally, previous studies have indicated that while nicotine (again highly fat soluble) is transferred into the fetal compartment up to five times the concentration in the maternal blood, cotinine concentrations in the fetal compartment were considerably lower than corresponding maternal serum levels. 19 Again, it has been suggested that cotinine adducts the placenta, preventing equilibration of concentrations between maternal and fetal systems. These studies support our current findings regarding cocaine and cotinine levels in umbilical cords. Again, as both the umbilical cord and the meconium are on the fetal side of the placenta, we would expect concordance in between both for drug detection, as was presented by Montgomery et al. 8 and Derauf et al. 15 Unfortunately, particularly for cotinine and cocaine, we conclude that the sensitivity of these tissues as a proxy marker is almost certainly less useful than maternal serum. This was also shown recently for meconium in a similar population. 7 In the current study, umbilical cord tissue seems to be a good matrix in which to measure marijuana use. This could be due to the fact that marijuana has a long terminal half-life in maternal tissues and a multiphasic elimination profile due to sequestration in fat. Thus, as the placenta presents no barrier to transport, as the THC leaches from maternal fat stores, it would be available for longer to fetal tissues as well.
A limitation of this study was a lack of uniform screening techniques for substance use. This was necessitated by the study design, which relied on de-identified clinical data and biologic specimens from a variety of prenatal care providers. While this may decrease the sensitivity of verbal screening in the study, and it seems that this is the case, as the rate of meth positivity is higher in the control groups than in the drug group, it may increase the generalizability of the study, as the subjects were from a wide array of backgrounds. This high rate of drug positivity in the control group again emphasizes the need for careful screening for substance abuse during pregnancy, using any of a variety of validated screening measures. Another limitation is the lack of information on environmental tobacco and drug exposure, again because of the study design.
A future direction of study will be using umbilical cord tissue as a means of confirming controls in a study of the placental effects of drugs, in which no other confirmatory measures are available. Indeed, based on the rates of detection reported herein, umbilical cord detection is a viable method for detecting the presence of illicit drugs, as the negative predictive values of the test were at least 89% for the main drugs we will be studying, namely, methamphetamine and marijuana.
In addition, given known differences in placental transport of cocaine and cotinine to the fetus, it is important to use a fetal tissue (such as umbilical cords, meconium, or fetal hair) in order to obtain an accurate depiction of fetal drug exposure. In order to further define this relationship, future studies will center on determining maternal and fetal blood drug levels and comparing these to the levels observed in umbilical cords.
Another interesting finding is the high rate of marijuana positivity, despite low levels of self-reported marijuana use. Other studies in Hawaii have shown a self-reported marijuana use during the third trimester of pregnancy rate of 0.4 to 4.9%. 12, 20 Possible explanations include vast underreporting of direct marijuana use, which is a distinct possibility, and/or unwitting underreporting of marijuana contact through proximity. During pregnancy, cardiac output is increased by 30%, which directly increases pulmonary flow and favors uptake of substances across the alveolar membranes of the lung. 21 Hyperventilation, caused by increased progesterone levels and an increase in tidal volume during pregnancy, may also promote the alveolar passage of substances. These physiological changes, in the context of exposure to marijuana smoke, likely mean that during pregnancy, women experience much higher uptake of cannabinoids from environmental exposure than non-pregnant women. Additionally, our high positive rate for marijuana exposure in fetuses, if correct, indicates an extremely high level of marijuana use in the Hawaiian population. Indeed, this statement would seem to be confirmed by a multicenter study performed in military personnel, which reported an unusually high rate of methamphetamine and marijuana use in the Hawaiian population. 22 This clearly requires further study, as there are few definitive works in the literature on the effects of marijuana in pregnancy including developmental effects of this exposure on fetal and infant brain development.
Conclusion
This is the first study to measure cotinine levels in umbilical cord tissue, and is also the first study to compare findings from umbilical cord tissue with self-reported drug use. Our finding is that umbilical cords are very predictive for drug use (at least 89% for all drugs tested). Further study is needed to compare umbilical cord cotinine levels with maternal and cord serum levels to confirm if this is a viable method to corroborate maternal smoking habits and fetal exposure to second-hand smoke. Perhaps, the most surprising and troubling finding presented herein was the extremely high rate of marijuana use/exposure in pregnant women in Hawaii. The study was not specifically designed to investigate population trends in drug use, rather to assess the use of umbilical cords as proxy markers of drug use. However, we have presented compelling evidence for a silent epidemic of marijuana use/ exposure during pregnancy in Hawaii, which requires urgent and careful further study.
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